SecBot SecBot
SECBOTREPLAY Home › Report › ACAD

ACAD · Acadia Pharmaceuticals settled a stockholder derivative lawsuit related…

ACADIA PHARMACEUTICALS INC · 8-K filed Sep 11, 2026 at 17:15 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Sep 11, 2026 at 17:15 ET

Acadia Pharmaceuticals settled a stockholder derivative lawsuit related to alleged misleading statements about its pimavanserin sNDA and insider trading. The settlement, preliminarily approved by the court on August 24, 2026, requires Acadia to adopt corporate governance reforms (audit committee enhancements, scientific committee charter, disclosure committee, insider trading policy changes, clawback policy) and pay $1.5M in plaintiffs' attorneys' fees from insurance. The derivative claims are dismissed with prejudice, but the related securities class action and opt-out action remain pending.

  • Derivative lawsuit settlement preliminarily approved by SD California court on August 24, 2026
  • Settlement requires Acadia to adopt and maintain corporate governance reforms for at least 4 years
  • Plaintiffs' attorneys' fees of $1.5M to be paid by company's insurers, not from company assets
  • Related securities class action (City of Birmingham Relief and Retirement System) and opt-out action (Alger Dynamic Opportunities Fund) remain pending

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access